JPWO2020247421A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247421A5 JPWO2020247421A5 JP2021571800A JP2021571800A JPWO2020247421A5 JP WO2020247421 A5 JPWO2020247421 A5 JP WO2020247421A5 JP 2021571800 A JP2021571800 A JP 2021571800A JP 2021571800 A JP2021571800 A JP 2021571800A JP WO2020247421 A5 JPWO2020247421 A5 JP WO2020247421A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- modified release
- release formulation
- formulation
- based agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 91
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 25
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 22
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 21
- 229930006000 Sucrose Natural products 0.000 claims description 21
- 239000005720 sucrose Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 17
- 239000008188 pellet Substances 0.000 claims description 14
- 235000019846 buffering salt Nutrition 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 239000000337 buffer salt Substances 0.000 claims description 10
- 239000007771 core particle Substances 0.000 claims description 10
- 239000002702 enteric coating Substances 0.000 claims description 10
- 238000009505 enteric coating Methods 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 208000019095 Radiation-induced disease Diseases 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 5
- 239000002356 single layer Substances 0.000 claims description 5
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical group CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims description 2
- 206010067994 Mucosal atrophy Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000036962 time dependent Effects 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 230000004584 weight gain Effects 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 2
- 206010002482 Angiosclerosis Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024206717A JP2025027050A (ja) | 2019-06-03 | 2024-11-27 | アルカリホスファターゼ製剤及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856309P | 2019-06-03 | 2019-06-03 | |
| US62/856,309 | 2019-06-03 | ||
| PCT/US2020/035814 WO2020247421A1 (en) | 2019-06-03 | 2020-06-03 | Alkaline phosphatase formulations and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206717A Division JP2025027050A (ja) | 2019-06-03 | 2024-11-27 | アルカリホスファターゼ製剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535401A JP2022535401A (ja) | 2022-08-08 |
| JP2022535401A5 JP2022535401A5 (https=) | 2023-06-07 |
| JPWO2020247421A5 true JPWO2020247421A5 (https=) | 2023-06-07 |
Family
ID=73653033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571800A Pending JP2022535401A (ja) | 2019-06-03 | 2020-06-03 | アルカリホスファターゼ製剤及びその使用 |
| JP2024206717A Pending JP2025027050A (ja) | 2019-06-03 | 2024-11-27 | アルカリホスファターゼ製剤及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206717A Pending JP2025027050A (ja) | 2019-06-03 | 2024-11-27 | アルカリホスファターゼ製剤及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220323367A1 (https=) |
| EP (1) | EP3975999A4 (https=) |
| JP (2) | JP2022535401A (https=) |
| KR (1) | KR20220016199A (https=) |
| CN (2) | CN119896726A (https=) |
| AU (1) | AU2020287084B2 (https=) |
| CA (1) | CA3142240A1 (https=) |
| WO (1) | WO2020247421A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220005560A (ko) | 2019-05-06 | 2022-01-13 | 신세틱 바이오로직스, 인코퍼레이티드 | 알칼리성 포스페이트-기반 종양학 치료제 |
| KR20220111693A (ko) | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법 |
| US12083169B2 (en) * | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| WO2023141560A2 (en) * | 2022-01-20 | 2023-07-27 | Synthetic Biologics, Inc. | Alkaline phosphatase for use in oncology |
| US20260048103A1 (en) * | 2022-08-09 | 2026-02-19 | Theriva Biologics, Inc. | Treatment or prevention of gastrointestinal immunotherapy side effects |
| CN118216620A (zh) * | 2024-05-24 | 2024-06-21 | 中国农业科学院北京畜牧兽医研究所 | 牛碱性磷酸酶bIAP作为饲料添加剂用于抵抗产气荚膜梭菌感染肉鸡所致感染症状的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7048914B2 (en) | 2002-12-12 | 2006-05-23 | Zoltan Laboratories | Placental alkaline phosphatase to control diabetes |
| ES2280891T3 (es) * | 2003-12-04 | 2007-09-16 | F. Hoffmann-La Roche Ag | Metodo para obtener polinucleotidos circulares mutados y/o quimericos. |
| CA2554683C (en) * | 2004-02-04 | 2014-06-10 | Pharmaaware Sepsis B.V. | Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers |
| WO2008001341A1 (en) * | 2006-06-27 | 2008-01-03 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| EP1985697A1 (en) * | 2007-04-27 | 2008-10-29 | AM-Pharma B.V. | Modified phosphatases |
| WO2010025267A2 (en) | 2008-08-29 | 2010-03-04 | The General Hospital Corporation | Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| EP2570120B1 (en) * | 2010-06-08 | 2017-10-25 | Kobe Gakuin Educational Foundation | Coated particle and method for producing coated particle |
| KR101243938B1 (ko) * | 2010-10-19 | 2013-03-19 | 이희엽 | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 |
| US20130251701A1 (en) | 2010-10-22 | 2013-09-26 | Zoltan Kiss Consulting | Alkaline phosphatase to correct insulin resistance, hyperinsulinemia, and dyslipidemia |
| CN102743339B (zh) * | 2012-07-20 | 2015-01-14 | 苏州大学 | 一种碱性磷酸酶纳微颗粒及其制备方法 |
| CA2899925A1 (en) | 2013-02-04 | 2014-08-07 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| EP3125870A4 (en) | 2014-04-04 | 2017-12-13 | Alba Therapeutics Corporation | Methods of treating celiac disease with larazotide |
| RU2016138847A (ru) | 2014-04-07 | 2018-05-07 | Хэлф Ресерч, Инк. | Композиции и способы, относящиеся к покоящимся предрасположенным к старению клеткам (DSPC) |
| CN106890326A (zh) | 2015-12-21 | 2017-06-27 | 青岛黄海制药有限责任公司 | 一种含复合磷酸酯酶的肠溶微丸及其制备 |
| AU2017297718B2 (en) * | 2016-07-11 | 2023-06-08 | Contera Pharma A/S | Pulsatile drug delivery system for treating morning akinesia |
| WO2018175413A1 (en) * | 2017-03-21 | 2018-09-27 | Synthetic Biologics, Inc. | Alkaline phosphatase formulations |
| WO2019183208A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase formulations |
-
2020
- 2020-06-03 US US17/615,942 patent/US20220323367A1/en active Pending
- 2020-06-03 AU AU2020287084A patent/AU2020287084B2/en active Active
- 2020-06-03 CA CA3142240A patent/CA3142240A1/en active Pending
- 2020-06-03 CN CN202411827248.5A patent/CN119896726A/zh active Pending
- 2020-06-03 WO PCT/US2020/035814 patent/WO2020247421A1/en not_active Ceased
- 2020-06-03 CN CN202080053704.9A patent/CN114222561A/zh active Pending
- 2020-06-03 JP JP2021571800A patent/JP2022535401A/ja active Pending
- 2020-06-03 EP EP20818286.5A patent/EP3975999A4/en active Pending
- 2020-06-03 KR KR1020217043142A patent/KR20220016199A/ko active Pending
-
2024
- 2024-11-27 JP JP2024206717A patent/JP2025027050A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3725542B2 (ja) | ピコサルフェート剤形 | |
| JP4936577B2 (ja) | 多層調節放出性製薬学的投薬形態 | |
| JP5783489B2 (ja) | トロスピウムの１日１回剤形 | |
| CN109310642B (zh) | 美沙拉嗪的口服药物组合物 | |
| BRPI0707324A2 (pt) | sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos | |
| AU1279592A (en) | Delayed release oral dosage forms for treatment of intestinal disorders | |
| JPS63139128A (ja) | Ｌ―ドーパ含有組成物 | |
| KR20130086128A (ko) | 복용 용이성 고형 제제 | |
| US20170258869A1 (en) | Pharmaceutical Compositions for Colon-Specific Delivery | |
| CN101010070A (zh) | 药物组合物 | |
| BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
| JP2017533211A (ja) | アマンタジン組成物を投与する方法 | |
| CN113521029A (zh) | 包含富马酸二甲酯的药物珠粒制剂 | |
| JP6902043B2 (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| JPWO2020247421A5 (https=) | ||
| EP3445360B1 (en) | Oral pharmaceutical compositions of nicotinamide | |
| JP4771956B2 (ja) | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 | |
| CN105025883A (zh) | 右哌甲酯或其盐的调节释放的药物组合物 | |
| CN104666271B (zh) | 一种用于局部晚期直肠癌治疗的控释药物制剂的制备方法 | |
| CN104490839A (zh) | 一种用于局部晚期直肠癌治疗的控释药物制剂 | |
| WO2017156214A1 (en) | Pharmaceutical compositions for colon-specific delivery | |
| US11596607B2 (en) | Polymer based formulation for release of drugs and bioactives at specific GIT sites | |
| JP2008535920A (ja) | 癌の治療のための、フルオロシチジン誘導体を含む改変放出組成物 | |
| WO2025215658A1 (en) | Pharmaceutical compositions of ketotifen | |
| JP2021535167A5 (https=) |